TNG — Transgene SA Cashflow Statement
0.000.00%
Last trade - 00:00- €115.57m
- €99.09m
- €6.08m
Annual cashflow statement for Transgene SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.2 | -19.5 | -32.8 | -22.3 | -34 |
| Depreciation | |||||
| Non-Cash Items | -4.62 | -2.13 | 5.72 | -6.85 | -1.61 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -8.68 | -6.76 | 5.09 | -7.07 | 10.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -28.7 | -25.9 | -20.3 | -34.7 | -23.5 |
| Capital Expenditures | -0.811 | -0.671 | -1.5 | -2.67 | -3.07 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 18.6 | -5.12 | 21.8 | 37.2 | -0.14 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 17.7 | -5.79 | 20.3 | 34.6 | -3.21 |
| Financing Cash Flow Items | 27.9 | 0.452 | -0.196 | 12.6 | 35.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.9 | 32.3 | -1.48 | 11.4 | 27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.93 | 0.634 | -1.51 | 11.3 | 1 |